Showing 2,658 results

Filters Content type: News, Editors' picks Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

Hepatitis C treatment

Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C

News
25 November 2014
Hepatitis C treatment

Deaths of Japanese patients prompt label change for simeprevir

Editor's pick
HCP Live
24 November 2014
New & experimental hepatitis C treatment

CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

Editor's pick
AbbVie press release
21 November 2014
Hepatitis C treatment

Ooh La La: France Negotiates a Steep Discount for Sovaldi From Gilead

Editor's pick
Wall Street Journal
21 November 2014
Hepatitis C treatment

AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection

News
21 November 2014
New & experimental hepatitis C treatment

Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients

News
19 November 2014
Hepatitis C treatment

NHS asks Nice to delay ground-breaking hepatitis C drug

Editor's pick
Channel 4 News (blog)
19 November 2014
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir)

Editor's pick
Gilead press release
19 November 2014
Hepatitis C treatment

Practical steps to eliminating hepatitis C: a consensus for London

Editor's pick
London Joint Working Group on Substance Use and Hepatitis C
17 November 2014
Hepatitis C treatment

Interim Revision of Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Editor's pick
AidsInfo
17 November 2014
Hepatitis B

Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients

News
17 November 2014
Hepatitis C treatment

Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection

News
13 November 2014
Hepatitis C treatment

Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4

News
13 November 2014
Hepatitis C treatment

Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis

News
12 November 2014
Hepatitis & HIV

People living with HIV have high survival rates after liver transplants due to HCC

News
12 November 2014
Hepatitis B

Hepatitis B testing and treatment rates are low among US veterans

News
11 November 2014
New & experimental hepatitis C treatment

Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis

News
11 November 2014
Hepatitis C transmission & prevention

Young drug injectors on opioid maintenance therapy have lower risk of hepatitis C infection

News
11 November 2014
Hepatitis C treatment

New HCV drugs pass muster in real world

Editor's pick
MedPage Today
11 November 2014
New & experimental hepatitis C treatment

New pill that can cure hepatitis C approved for patients in Scotland

Editor's pick
STV
11 November 2014
New & experimental hepatitis C treatment

Merck’s four-week treatment for hepatitis C misses the mark

Editor's pick
Wall Street Journal
11 November 2014
New & experimental hepatitis C treatment

Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis

Editor's pick
Bristol-Myers Squibb press release
10 November 2014
New & experimental hepatitis C treatment

ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients

Editor's pick
Bristol-Myers Squibb press release
10 November 2014
New & experimental hepatitis C treatment

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)

Editor's pick
Achillion press release
10 November 2014